Overview

AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer

Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving AZD2171 together with combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed and may kill more tumor cells. PURPOSE: This randomized clinical trial is studying how well giving AZD2171 together with combination chemotherapy works in treating women with locally advanced breast cancer.
Phase:
N/A
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Cediranib
Cyclophosphamide
Docetaxel
Doxorubicin
Liposomal doxorubicin